{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:15:20Z","timestamp":1793232920591,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T00:00:00Z","timestamp":1500249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T00:00:00Z","timestamp":1500249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The rapid renal clearance of peptides\n                    <jats:italic>in vivo<\/jats:italic>\n                    limits this attractive platform for the treatment of a broad range of diseases that require prolonged drug half-lives. An intriguing approach for extending peptide circulation times works through a \u2018piggy-back\u2019 strategy in which peptides bind via a ligand to the long-lived serum protein albumin. In accordance with this strategy, we developed an easily synthesized albumin-binding ligand based on a peptide-fatty acid chimera that has a high affinity for human albumin (\n                    <jats:italic>K<\/jats:italic>\n                    <jats:sub>d<\/jats:sub>\n                    =39\u2009nM). This ligand prolongs the elimination half-life of cyclic peptides in rats 25-fold to over seven hours. Conjugation to a peptide factor XII inhibitor developed for anti-thrombotic therapy extends the half-life from 13 minutes to over five hours, inhibiting coagulation for eight hours in rabbits. This high-affinity albumin ligand could potentially extend the half-life of peptides in human to several days, substantially broadening the application range of peptides as therapeutics.\n                  <\/jats:p>","DOI":"10.1038\/ncomms16092","type":"journal-article","created":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T05:25:59Z","timestamp":1500269159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides"],"prefix":"10.1038","volume":"8","author":[{"given":"Alessandro","family":"Zorzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Middendorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Wilbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaycie","family":"Deyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Heinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,17]]},"reference":[{"key":"BFncomms16092_CR1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","volume":"20","author":"K Fosgerau","year":"2015","unstructured":"Fosgerau, K. & Hoffmann, T. Peptide therapeutics: current status and future directions. Drug Discov. Today 20, 122\u2013128 (2015).","journal-title":"Drug Discov. Today"},{"key":"BFncomms16092_CR2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.drudis.2013.10.011","volume":"19","author":"K Josephson","year":"2014","unstructured":"Josephson, K., Ricardo, A. & Szostak, J. W. mRNA display: from basic principles to macrocycle drug discovery. Drug Discov. Today 19, 388\u2013399 (2014).","journal-title":"Drug Discov. Today"},{"key":"BFncomms16092_CR3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cbpa.2015.01.023","volume":"26","author":"T Morioka","year":"2015","unstructured":"Morioka, T., Loik, N. D., Hipolito, C. J., Goto, Y. & Suga, H. Selection-based discovery of macrocyclic peptides for the next generation therapeutics. Curr. Opin. Chem. Biol. 26, 34\u201341 (2015).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"BFncomms16092_CR4","first-page":"608","volume":"19","author":"WC Duckworth","year":"1998","unstructured":"Duckworth, W. C., Bennett, R. G. & Hamel, F. G. Insulin degradation: progress and potential. Endocr. Rev. 19, 608\u2013624 (1998).","journal-title":"Endocr. Rev."},{"key":"BFncomms16092_CR5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF00634710","volume":"256","author":"M Gonser","year":"1995","unstructured":"Gonser, M. Labor induction and augmentation with oxytocin: pharmacokinetic considerations. Arch. Gynecol. Obstet. 256, 63\u201366 (1995).","journal-title":"Arch. Gynecol. Obstet."},{"key":"BFncomms16092_CR6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nchembio.1907","volume":"11","author":"SC Penchala","year":"2015","unstructured":"Penchala, S. C. et al. A biomimetic approach for enhancing the in vivo half-life of peptides. Nat. Chem. Biol. 11, 793\u2013798 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"BFncomms16092_CR7","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1517\/14712598.2016.1165661","volume":"16","author":"RE Kontermann","year":"2016","unstructured":"Kontermann, R. E. Half-life extended biotherapeutics. Expert Opin. Biol. Ther. 16, 903\u2013915 (2016).","journal-title":"Expert Opin. Biol. Ther."},{"key":"BFncomms16092_CR8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jconrel.2015.06.006","volume":"211","author":"M Bern","year":"2015","unstructured":"Bern, M., Sand, K. M. K., Nilsen, J., Sandlie, I. & Andersen, J. T. The role of albumin receptors in regulation of albumin homeostasis: implications for drug delivery. J. Controlled Release 211, 144\u2013162 (2015).","journal-title":"J. Controlled Release"},{"key":"BFncomms16092_CR9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrd.2015.36","volume":"15","author":"AN Zaykov","year":"2016","unstructured":"Zaykov, A. N., Mayer, J. P. & DiMarchi, R. D. Pursuit of a perfect insulin. Nat. Rev. Drug Discov. 15, 425\u2013439 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFncomms16092_CR10","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cmdc.201600374","volume":"11","author":"SB van Witteloostuijn","year":"2016","unstructured":"van Witteloostuijn, S. B., Pedersen, S. L. & Jensen, K. J. Half-life extension of biopharmaceuticals using chemical methods: alternatives to PEGylation. ChemMedChem 11, 2474\u20132495 (2016).","journal-title":"ChemMedChem"},{"key":"BFncomms16092_CR11","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1042\/bj3120725","volume":"312","author":"P Kurtzhals","year":"1995","unstructured":"Kurtzhals, P. et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem. J. 312, 725\u2013731 (1995).","journal-title":"Biochem. J."},{"key":"BFncomms16092_CR12","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1007\/s11095-012-0739-z","volume":"29","author":"I Jonassen","year":"2012","unstructured":"Jonassen, I. et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm. Res. 29, 2104\u20132114 (2012).","journal-title":"Pharm. Res."},{"key":"BFncomms16092_CR13","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/jm9909645","volume":"43","author":"LB Knudsen","year":"2000","unstructured":"Knudsen, L. B. et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 43, 1664\u20131669 (2000).","journal-title":"J. Med. Chem."},{"key":"BFncomms16092_CR14","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1016\/S0960-894X(02)00610-8","volume":"12","author":"MF Koehler","year":"2002","unstructured":"Koehler, M. F. et al. Albumin affinity tags increase peptide half-life in vivo. Bioorg. Med. Chem. Lett. 12, 2883\u20132886 (2002).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFncomms16092_CR15","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1002\/anie.200704936","volume":"47","author":"CE Dumelin","year":"2008","unstructured":"Dumelin, C. E. et al. A portable albumin binder from a DNA-encoded chemical library. Angew Chem. Int. Ed. Engl. 47, 3196\u20133201 (2008).","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"BFncomms16092_CR16","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1002\/anie.201410736","volume":"54","author":"RM Franzini","year":"2015","unstructured":"Franzini, R. M. et al. Identification of structure-activity relationships from screening a structurally compact DNA-encoded chemical library. Angew. Chem. Int. Ed. Engl. 54, 3927\u20133931 (2015).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"BFncomms16092_CR17","doi-asserted-by":"crossref","first-page":"35035","DOI":"10.1074\/jbc.M205854200","volume":"277","author":"MS Dennis","year":"2002","unstructured":"Dennis, M. S. et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. 277, 35035\u201335043 (2002).","journal-title":"J. Biol. Chem."},{"key":"BFncomms16092_CR18","doi-asserted-by":"crossref","first-page":"10187","DOI":"10.1021\/jm301276e","volume":"55","author":"A Angelini","year":"2012","unstructured":"Angelini, A., Morales-Sanfrutos, J., Diderich, P., Chen, S. & Heinis, C. Bicyclization and tethering to albumin yields long-acting peptide antagonists. J. Med. Chem. 55, 10187\u201310197 (2012).","journal-title":"J. Med. Chem."},{"key":"BFncomms16092_CR19","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1021\/cb200478t","volume":"7","author":"A Angelini","year":"2012","unstructured":"Angelini, A. et al. Bicyclic peptide inhibitor reveals large contact interface with a protease target. ACS Chem. Biol. 7, 817\u2013821 (2012).","journal-title":"ACS Chem. Biol."},{"key":"BFncomms16092_CR20","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nchembio.184","volume":"5","author":"C Heinis","year":"2009","unstructured":"Heinis, C., Rutherford, T., Freund, S. & Winter, G. Phage-encoded combinatorial chemical libraries based on bicyclic peptides. Nat. Chem. Biol. 5, 502\u2013507 (2009).","journal-title":"Nat. Chem. Biol."},{"key":"BFncomms16092_CR21","doi-asserted-by":"crossref","unstructured":"Peters, T. Jr All About Albumin: Biochemistry, Genetics, and Medical Applications Academic Press (1996).","DOI":"10.1016\/B978-012552110-9\/50006-4"},{"key":"BFncomms16092_CR22","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/cmdc.201200071","volume":"7","author":"V Baeriswyl","year":"2012","unstructured":"Baeriswyl, V. et al. Bicyclic peptides with optimized ring size inhibit human plasma kallikrein and its orthologues while sparing paralogous proteases. ChemMedChem 7, 1173\u20131176 (2012).","journal-title":"ChemMedChem"},{"key":"BFncomms16092_CR23","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.drudis.2014.06.024","volume":"19","author":"E Kenne","year":"2014","unstructured":"Kenne, E. & Renn\u00e9, T. Factor XII: a drug target for safe interference with thrombosis and inflammation. Drug Discov. Today 19, 1459\u20131464 (2014).","journal-title":"Drug Discov. Today"},{"key":"BFncomms16092_CR24","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1021\/acschembio.5b00103","volume":"10","author":"V Baeriswyl","year":"2015","unstructured":"Baeriswyl, V. et al. A synthetic factor XIIa inhibitor blocks selectively intrinsic coagulation initiation. ACS Chem. Biol. 10, 1861\u20131870 (2015).","journal-title":"ACS Chem. Biol."},{"key":"BFncomms16092_CR25","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/cbic.201600336","volume":"17","author":"J Wilbs","year":"2016","unstructured":"Wilbs, J., Middendorp, S. J. & Heinis, C. Improving the binding affinity of in vitro evolved cyclic peptides by inserting atoms into the macrocycle backbone. ChemBioChem 17, 2299\u20132303 (2016).","journal-title":"ChemBioChem"},{"key":"BFncomms16092_CR26","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1021\/acs.jmedchem.6b01548","volume":"60","author":"SJ Middendorp","year":"2017","unstructured":"Middendorp, S. J. et al. Peptide macrocycle inhibitor of coagulation factor XII with subnanomolar affinity and high target selectivity. J. Med. Chem. 60, 1151\u20131158 (2017).","journal-title":"J. Med. Chem."},{"key":"BFncomms16092_CR27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00418343","volume":"39","author":"J Markussen","year":"1996","unstructured":"Markussen, J. et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39, 281\u2013288 (1996).","journal-title":"Diabetologia"},{"key":"BFncomms16092_CR28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/protein\/gzl011","volume":"19","author":"A Nguyen","year":"2006","unstructured":"Nguyen, A. et al. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng. Des. Sel. 19, 291\u2013297 (2006).","journal-title":"Protein Eng. Des. Sel."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncomms16092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms16092","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ncomms16092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms16092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T19:56:31Z","timestamp":1671738991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncomms16092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,17]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12,22]]}},"alternative-id":["BFncomms16092"],"URL":"https:\/\/doi.org\/10.1038\/ncomms16092","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727815153.793537355","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.727815153.793534741","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,17]]},"assertion":[{"value":"21 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.H. is a scientific founder of Bicycle Therapeutics. The remaining authors declare no conflict of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16092"}}